Dermata Therapeutics (DRMA) Fundamental Analysis: Revenue, Earnings & Valuation

8.82 / 10

Outperform

Fundamentally DRMA excels with strong interest coverage (35.1), high PB‑ROE (4.31) and rapid revenue growth (operating revenue YoY 177%). Inventory turnover is solid (103.9). However, current liabilities equal total liabilities and long‑term debt to working capital are high, posing risk.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight39.04%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.54%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.45%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value100.00

Score0/3

Weight-16.50%

1M Return-4.96%

PB-ROE

Value4.31

Score3/3

Weight49.17%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value6.39

Score0/3

Weight-16.96%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.53%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.22%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.28%

1M Return-1.13%

Asset-MV

Value-0.49

Score2/3

Weight57.74%

1M Return11.12%

Is DRMA undervalued or overvalued?

DRMA scores 8.82/10 on fundamentals and holds a Discounted valuation at present. Backed by its -194.20% ROE, 0.00% net margin, -0.69 P/E ratio, 0.83 P/B ratio, and 89.84% earnings growth, these metrics solidify its Outperform investment rating.